Skip to main content

Table 2 Response rate

From: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

Best response N = 42
CR 1
PR 10
SD 22
PD 6
NE 3
ORR (%) 26.2
DCR (%) 78.5
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, ORR objective response rate, DCR disease control rate